Salbutamol MDI - GSK
Alternative Names: AH-3365; Albuterol; Albuterol HFA; albuterol hydrofluoroalkane; salbutamol (albuterol) MDI; salbutamol - metered dose; Salbutamol HFA; Salbutamol hydrofluoroalkane; salbutamol pressurised inhalation; Salbutamol sulfate MDI - GlaxoSmithKline; VentolinLatest Information Update: 18 Jun 2024
At a glance
- Originator GSK
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Phenols; Small molecules; Tocolytics
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Asthma
Most Recent Events
- 18 Jun 2024 Chemical structure information added
- 31 May 2024 Phase-III clinical trials in Asthma in United Kingdom, Thailand, Spain, Poland, Philippines, Panama, Italy, Greece, France, Canada, Australia, Argentina, USA (PO) (NCT06261957) (EudraCT2023-509001-76-00)
- 30 May 2024 GlaxoSmithKline plans a phase I trial for Asthma (Treatment-experienced) (PO, Inhalant) (NCT06433921)